Some neuroscientists are daring to wield the technologies to probe one powerful group of internal brain states: emotions. Others are applying them to states such as motivation, or existential drives such as thirst. Researchers are even finding signatures of states in their data for which they have no vocabulary.
Neuroscientists are scrutinizing huge piles of data to learn how brains create emotions and other internal states such as aggression and desire.
The answer is in their genes—especially those that encode for basic life functions, such as metabolism. Thanks to the lowly C. elegans worm, we’ve uncovered genes and molecular pathways, such as insulin-like growth factor 1 (IGF-1) signaling that extends healthy longevity in yeast, flies, and mice (and maybe us). Too nerdy? Those pathways also inspired massive scientific and popular interest in metformin, hormones, intermittent fasting, and even the ketogenic diet. To restate: worms have inspired the search for our own fountain of youth.
Still, that’s just one success story. How relevant, exactly, are those genes for humans? We’re rather a freak of nature. Our aging process extends for years, during which we experience a slew of age-related disorders. Diabetes. Heart disease. Dementia. Surprisingly, many of these don’t ever occur in worms and other animals. Something is obviously amiss.
In this month’s Nature Metabolism, a global team of scientists argued that it’s high time we turn from worm to human. The key to human longevity, they say, lies in the genes of centenarians. These individuals not only live over 100 years, they also rarely suffer from common age-related diseases. That is, they’re healthy up to their last minute. If evolution was a scientist, then centenarians, and the rest of us, are two experimental groups in action.
But have you ever wondered: how well do those maps represent my brain? After all, no two brains are alike. And if we’re ever going to reverse-engineer the brain as a computer simulation—as Europe’s Human Brain Project is trying to do—shouldn’t we ask whose brain they’re hoping to simulate?
Enter a new kind of map: the Julich-Brain, a probabilistic map of human brains that accounts for individual differences using a computational framework. Rather than generating a static PDF of a brain map, the Julich-Brain atlas is also dynamic, in that it continuously changes to incorporate more recent brain mapping results. So far, the map has data from over 24,000 thinly sliced sections from 23 postmortem brains covering most years of adulthood at the cellular level. But the atlas can also continuously adapt to progress in mapping technologies to aid brain modeling and simulation, and link to other atlases and alternatives.
In other words, rather than “just another” human brain map, the Julich-Brain atlas is its own neuromapping API—one that could unite previous brain-mapping efforts with more modern methods.
Last year information was released concerning rejuvenation of the thymus which resulted in a reversal of the epigenetic clock an average of 2.5 years in a small trial of 9 people costing $10,000 per person. You can get this done too. A company has formed called Intervene Immune which will take on volunteers for the process. It is not funded so you would have to pay out pf pocket though eventually the cost may come down and they can provide financing. You do not have to travel to California to get this done. Cost prohibits me, and I may or may not be eligible as I have IBS though that is not on the exclusion list. I emailed them concerning all this which is how I got the information.
https://www.surveymonkey.com/r/TRIIMX
The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may prevent or reverse key aspects of immunosenescence (immune system aging) and potentially prevent or reverse key parts of the aging process more generally. The study will evaluate biomarkers for epigenetic aging and immunosenescence, as well as evaluate established clinical measures and risk factors for prevention of physical frailty, cancer, cardiovascular disease, diabetes, dementia, and also infectious diseases, including flu and COVID-19.
The study uses multiple agents in combination with personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA, in a similar manner to how the combination treatment was applied in the earlier TRIIM trial at Stanford, which demonstrated strong statistical significance for the primary efficacy endpoints that will be evaluated in TRIIM-X. Somatropin is approved by the FDA for adult growth hormone deficiency and its use in the study is guided by prior safety data established for that use and also based on safety data available on its prior use in the TRIIM trial and in clinical practice in healthy elderly individuals. There will also be control groups that enable testing of biomarker variability and the contribution of individual medications within the combination treatment.
The objective of the study is to obtain information needed for designing an effective personalized and adaptive treatment regimen for a larger and more diverse study population, and to obtain additional proof of principle for the new use of the medications and biomarkers for preventive medicine. The duration of treatment in the TRIIM-X trial will be 12 months.
A supersensitive dopamine detector can help in the early diagnosis of several disorders that result in too much or too little dopamine, according to a group led by Penn State and including Rensselaer Polytechnic Institute and universities in China and Japan.
Dopamine is an important neurotransmitter that can be used to diagnose disorders such as Parkinson’s disease, Alzheimer’s disease and schizophrenia.
“If you can develop a very sensitive, yet simple-to-use and portable, detector that can identify a wide range of dopamine concentration, for instance in sweat, that could help in non-invasive monitoring of an individual’s health,” said Aida Ebrahimi, assistant professor of electrical engineering, Penn State, and a corresponding author on a paper published Aug. 7 in Science Advances.
Just like a nostalgic grandparent flipping through old photo albums, our brains constantly replay memories from past events in our lives as we sleep.
It may seem overly sentimental at first, but our minds aren’t just looking to reminisce and remember the good times. All of that brain activity while dreaming serves to strengthen and preserve existing memories, all while simultaneously finding some room for any new memories we may have made over the previous day.
Those are the main findings from a fascinating new study just released by the University of California, San Diego that investigated neural activity during sleep. The research team at UCSD says that no memory is set in stone within our minds; any memory can be lost, and sleep is when our minds rejuvenate old memories via replay and refine/make room for new memories.
An intriguing new study, from a team of Swiss researchers, has revealed neural activity during REM sleep in a particular region of the brain known to affect appetite and feeding behaviors significantly influences waking eating patterns.
Despite a hefty volume of robust study, REM sleep is still a mysterious and unique sleep phase. Named after the rapid eye movements that occur in all mammals during this sleep phase, it has also been referred to as paradoxical sleep, due to the strange similarity in brain activity between waking states and REM sleep.
The new research homed in on a brain region called the lateral hypothalamus. This tiny brain region, found in all mammals, is known to play a fundamental role in food intake, compulsive behavior, and a number of other physiological processes.
It’s also worth noting that some water already naturally contains low amounts of lithium. And in research published last week in The British Journal of Psychiatry, scientists from a cohort of U.K. universities identified a link that naturally-present lithium and lower suicide rates.
Therefore, they suggest, more lives could be saved by putting the drug in high-risk communities’ water supplies.
“In these unprecedented times of COVID-19 pandemic and the consequent increase in the incidence of mental health conditions, accessing ways to improve community mental health and reduce the incidence of anxiety, depression and suicide is ever more important,” Anjum Memon, lead author and epidemiology chair at Brighton and Sussex Medical School, said in a press release.